Chief Human Resources Officer

President

Revolution Medicines to Present Updated Elironrasib Safety and Efficacy Data in Patients with KRAS G12C Non-Small Cell Lung Cancer Following Treatment with a KRAS(OFF) G12C Inhibitor

Tango Therapeutics Reports Positive Data from Ongoing Phase 1/2 Study with Vopimetostat (TNG462) in Patients with MTAP-deleted Cancers

Tango Therapeutics Touts Encouraging Data From Early-Stage Cancer Trial, Raises Capital To Fund Advancement

Revolution Medicines pancreatic cancer treatment granted orphan status

Vice President, Global Commercial Development Disease Area Lead

Revolution Medicines is a clinical-stage precision oncology company focused on developing novel targeted therapies to inhibit frontier targets in RAS-addicted cancers. The role involves leading global oncology marketing capabilities, including strategy and execution for product launches and brand management.

VP, Talent Acquisition

Executive Director, Head of Talent Acquisition

Senior Vice President, Commercial

Vice President Commercial Development

Associate Director, Commercial Development

Sign up with Google

Sign in with Google